What is being studied?
An investigational therapy for newly diagnosed GBM, added to standard care.
Information for Patients and Caregivers
Alpheus is evaluating an investigational therapy for newly diagnosed glioblastoma in a clinical trial. Participants continue standard-of-care treatment as directed by their care team. To learn more and see whether you may qualify, visit BrainCancerTrial.com.
About the Trial
How Our Therapy Works
Frequently Asked Questions
What is the study about?
This study is evaluating an investigational therapy that combines an oral drug, 5-aminolevulinic acid (5-ALA), with low-intensity, non-invasive ultrasound delivered across the affected brain hemisphere. The purpose is to understand whether this approach can be safely administered and whether it shows early signs of biological or clinical activity for people with glioblastoma (GBM).
In earlier, small studies (including in recurrent GBM), this approach was associated with encouraging biological and radiographic signals. These observations were seen in limited patient groups and require confirmation in larger, controlled trials. They should not be interpreted as evidence of established clinical benefit.
Will I still receive standard treatment?
Yes. Per the study protocol, all patients continue to receive standard-of-care treatments as determined by their care team. The investigational therapy is added in addition to these treatments; nothing is removed by participating in this study.
What does participation involve?
Eligible patients will take 5-ALA and undergo scheduled non-invasive ultrasound sessions (for example, monthly, as specified in the protocol) in addition to their standard treatment. Your study team will provide detailed information about visit schedules, assessments, and what to expect during participation.
Where can I learn more or check eligibility?
If you or someone you care for has been diagnosed with glioblastoma (GBM), you can learn more about the study and explore whether you may be eligible:
